AbCellera prices $200M equity offering to fund ABCL635 clinical development

Filed August 13, 2026 · Period ending August 12, 2026 · ~1 min read

Key Changes

• high

  AbCellera entered into an underwriting agreement for a public offering of 17.4M common shares at $9.75 and 3.1M pre-funded warrants at $9.74999, expecting net proceeds of ~$187M after fees.

  Item 1.01 verify on EDGAR →
• high

  Net proceeds will fund clinical advancement of the internal pipeline, specifically lead program ABCL635, plus working capital and general corporate purposes.

  Exhibit 99.1 view on EDGAR →
• medium

  Pre-funded warrants are immediately exercisable at $0.00001 per share with a 4.99% beneficial ownership cap (adjustable to 19.99% with 61 days' notice).

  Item 1.01 verify on EDGAR →